FDA — authorised 2 February 1979
- Application: NDA017378
- Marketing authorisation holder: BAXTER HLTHCARE
- Local brand name: PLASMA-LYTE A IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA authorised Plasma-Lyte A In Plastic Container on 2 February 1979
The FDA approved Plasma-Lyte A In Plastic Container for intravenous use on 2026-04-17. This approval was granted to EXTROVIS under the standard expedited pathway. Plasma-Lyte A In Plastic Container is a solution containing sodium acetate, intended for intravenous administration.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 2 February 1979; FDA authorised it on 4 May 1983; FDA authorised it on 30 October 2017.
BAXTER HLTHCARE holds the US marketing authorisation.